Stay updated on Pembrolizumab in Recurrent PCNSL Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Recurrent PCNSL Clinical Trial page.

Latest updates to the Pembrolizumab in Recurrent PCNSL Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedRevision: v3.3.2 was added and v3.2.0 was removed on the page. This is a maintenance update that does not affect study details or how users interact with the page.SummaryDifference0.1%

- Check19 days agoChange DetectedTop-of-page government funding/status notice has been removed. The study details, eligibility criteria, and contact information remain unchanged.SummaryDifference0.4%

- Check41 days agoChange DetectedNo significant content changes are evident; the updates appear to be minor UI/visual adjustments without altering the study details such as eligibility, endpoints, or enrollment. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check62 days agoChange DetectedUpdate includes a prominent operating-status notice and a version upgrade from v3.1.0 to v3.2.0. The core effect is informing users about possible delays and the current open status of the NIH Clinical Center.SummaryDifference4%

- Check69 days agoChange DetectedThe page shows a version upgrade from v3.0.2 to v3.1.0 and adds a new extension/contact code (+43140400 ext 44450).SummaryDifference0.1%

- Check84 days agoChange DetectedOutput version updated from v3.0.1 to v3.0.2 and the 'Back to Top' element was removed; no changes to core content, pricing, stock, or time slots.SummaryDifference0.2%

Stay in the know with updates to Pembrolizumab in Recurrent PCNSL Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Recurrent PCNSL Clinical Trial page.